[HTML][HTML] Trends in cancer imaging
X Zhou, B Shi, G Huang, J Liu, W Wei - Trends in Cancer, 2024 - cell.com
Molecular imaging of cancer is a collaborative endeavor, uniting scientists and physicians
from diverse fields. Such collaboration is actively developing and translating cutting-edge …
from diverse fields. Such collaboration is actively developing and translating cutting-edge …
Whole-body HER2 heterogeneity identified on HER2 PET in HER2-negative,-low, and-positive metastatic breast cancer
B Eisses, JJL van Geel, AH Brouwers… - Journal of Nuclear …, 2024 - jnm.snmjournals.org
Understanding which patients with human epidermal growth factor receptor 2 (HER2)–
negative or–low metastatic breast cancer (MBC) benefit from HER2-targeted strategies is …
negative or–low metastatic breast cancer (MBC) benefit from HER2-targeted strategies is …
Affibody PET Imaging of HER2-Expressing Cancers as a Key to Guide HER2-Targeted Therapy
N Eissler, R Altena, A Alhuseinalkhudhur, O Bragina… - Biomedicines, 2024 - mdpi.com
Human epidermal growth factor receptor 2 (HER2) is a major prognostic and predictive
marker overexpressed in 15–20% of breast cancers. The diagnostic reference standard for …
marker overexpressed in 15–20% of breast cancers. The diagnostic reference standard for …
[64Cu]Cu-NOTA-Trastuzumab and [89Zr]Zr-DFO-Trastuzumab in Xenografts with Varied HER2 Expression
C Simó, S Shmuel, A Vanover… - Molecular …, 2024 - ACS Publications
Positron emission tomography (PET) has potential as a complementary technique to
biomarker analysis, especially for human epidermal growth factor receptor 2 (HER2) …
biomarker analysis, especially for human epidermal growth factor receptor 2 (HER2) …
The EANM-SNMMI guideline on the role of [18F] FDG-PET/CT in breast cancer: Important milestones and perspectives for the future
E Hindié - European Journal of Nuclear Medicine and Molecular …, 2024 - Springer
Appropriate selection of patients that require [18F] FDG PET/CT is very important. With a
100% agreement between authors, the EANM/SNMMI guideline recommend [18F] FDG …
100% agreement between authors, the EANM/SNMMI guideline recommend [18F] FDG …
Pre-treatment [18F] FDG PET/CT biomarkers for the prediction of antibody–drug conjugates efficacy in metastatic breast cancer
RD Seban, L Champion, A De Moura… - European Journal of …, 2024 - Springer
Purpose This study aimed to evaluate the association between pretreatment [18F] FDG
PET/CT-derived biomarkers and outcomes in metastatic breast cancer (mBC) patients …
PET/CT-derived biomarkers and outcomes in metastatic breast cancer (mBC) patients …
[HTML][HTML] Novel Molecular Classification of Breast Cancer with PET Imaging
NM Toàn - Medicina, 2024 - mdpi.com
Breast cancer is a heterogeneous disease characterized by a wide range of biomarker
expressions, resulting in varied progression, behavior, and prognosis. While traditional …
expressions, resulting in varied progression, behavior, and prognosis. While traditional …